AQUAGOLD® fine touch™ is a revolutionary microinjector that delivers a low dose of therapeutics into the skin using patented repeated motion microchannel injection technology.
In medical aesthetics, unlike other therapeutic areas, we often seek lower doses of product to achieve a more natural appearance and outcome. Full injections of maximum FDA-approved doses may not necessarily provide the optimal results you are looking for.
AQUAGOLD® fine touch™ is developed by Aquavit Pharmaceuticals, Inc., a New York based high-tech pharmaceutical company focused on providing personalized medicine. We are developing a comprehensive range of innovative pharmaceutical, biotech, and medical device technologies. AQUAGOLD® fine touch™ is one of the first of our products we introduced to empower and inspire our providers and their patients.
Our breadth of intellectual property covers the first in the world smart desktop compounding technology (PITO-001/QVT series) with AI integration and a big data platform (MAV series), personalized injectable formulations, microchannel mesotherapy, repeated motion delivery using microchannels, and any related combination therapy using microchannel technology. We are currently conducting in-depth research on the microchannel applications of neurotoxins (IMT-121). The success of this development will bring about the first FDA approved microchannel delivery of neurotoxins for the peri-orbital region in the US.
For consumers, we introduced the SKINWORKOUT®. This system includes the first in the US, sterilized pharmaceutical grade HA serums (U.R. and T.T.) for after-care and maintenance for any in-office treatments.
The A.S.A.P.!™ Microinfusion system allows the optimal infusion of any valuable serums we use at home. A perfect match with U.R. and T.T.!
As we continue to grow, Aquavit plans to bring an ever-increasing line of innovative products dedicated to serving the needs of our valued customers.